
QNCX Stock Forecast & Price Target
QNCX Analyst Ratings
Bulls say
Quince Therapeutics is well-positioned for success with its innovative AIDE technology and promising Phase 3 asset eDSP, which leverages the AIDE technology to encapsulate the drug DSP into a patient's own red blood cells. The company's focus on rare diseases and its differentiated approach to targeting vascular remodeling in pulmonary hypertension set it apart from other companies in the biotechnology space. Additionally, the upcoming data readouts for its Phase 2 BOS and PH-ILD trials provide potential catalysts for the stock. With its strong pipeline and potential for multiple blockbuster commercial opportunities, Quince Therapeutics is a stock to watch.
Bears say
Quince Therapeutics is up 85% in the last few weeks, making its undervaluation even more apparent. Despite the promising potential of LAM-001 and PH-ILD as the primary driver of the story, there may be challenges in replicating the initial human PH data and the lack of upcoming catalysts for ~1 year, creating a potential catalyst vacuum for the company.
This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
QNCX Analyst Forecast & Price Prediction
Start investing in QNCX
Order type
Buy in
Order amount
Est. shares
0 shares